Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Gains from Sales and Divestitures: 2022-2025

Historic Gains from Sales and Divestitures for Biofrontera (BFRI) over the last 2 years, with Sep 2025 value amounting to $225,000.

  • Biofrontera's Gains from Sales and Divestitures rose 4615.99% to $225,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $225,000, marking a year-over-year increase of 4615.99%. This contributed to the annual value of $4,771 for FY2024, which is 44.45% down from last year.
  • Biofrontera's Gains from Sales and Divestitures amounted to $225,000 in Q3 2025, which was up 4,615.99% from $4,771 recorded in Q4 2024.
  • In the past 5 years, Biofrontera's Gains from Sales and Divestitures registered a high of $170.1 million during Q2 2022, and its lowest value of $4,771 during Q2 2024.
  • In the last 3 years, Biofrontera's Gains from Sales and Divestitures had a median value of $6,680 in 2023 and averaged $42,748.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first slumped by 94.95% in 2023, then soared by 4,615.99% in 2025.
  • Quarterly analysis of 4 years shows Biofrontera's Gains from Sales and Divestitures stood at $8,504 in 2022, then rose by 0.99% to $8,588 in 2023, then tumbled by 44.45% to $4,771 in 2024, then spiked by 4,615.99% to $225,000 in 2025.
  • Its Gains from Sales and Divestitures was $225,000 in Q3 2025, compared to $4,771 in Q4 2024 and $4,771 in Q3 2024.